More evidence for coronary calcium as a measure of cardiovascular risk: Has anything changed?

JAMA

Volumn 311, Issue 3, 2014, Pages 247-248

  Greenland, Philip ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CALCIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGATSTON SCORE; AGE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL DECISION MAKING; CORONARY ARTERY CALCIUM SCORE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; EXERCISE; FEEDING BEHAVIOR; FRAMINGHAM RISK SCORE; HIGH RISK PATIENT; HUMAN; INDIVIDUALIZATION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; NUTRITIONAL HEALTH; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SMOKING; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; WEIGHT CONTROL;

CALCIUM; CORONARY DISEASE; CORONARY VESSELS; FEMALE; HUMANS; MALE; PLAQUE, ATHEROSCLEROTIC;

EID: 84892657701     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.282536     Document Type: Review

References (17)

1. Dandona S, Stewart AF, Roberts R. Genomics: is it ready for primetime? Med Clin North Am. 2012;96(1):113-122.
2. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J III. Factors of risk in the development of coronary heart disease - six year follow-up experience: the Framingham Study. Ann Intern Med. 1961;55:33-50.
3. Pearson TA, Palaniappan LP, Artinian NT, et al; American Heart Association Council on Epidemiology and Prevention. American Heart Association guide for improving cardiovascular health at the community level, 2013 update: a scientific statement for public health practitioners, healthcare providers, and health policy makers. Circulation. 2013;127(16):1730-1753.
4. Pearson TA, Blair SN, Daniels SR, et al; American Heart Association Science Advisory and Coordinating Committee. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106(3):388-391.
5. Lloyd-Jones DM, Hong Y, Labarthe D, et al; American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond. Circulation. 2010;121(4):586-613.
6. Lonn E, Yusuf S. Polypill: the evidence and the promise. Curr Opin Lipidol. 2009;20(6):453-459.
7. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol. 1976;38(1):46-51.
8. Hopkins PN, Williams RR. A survey of 246 suggested coronary risk factors. Atherosclerosis. 1981;40(1):1-52.
9. Greenland P, Alpert JS, Beller GA, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122(25):e584- e636.
10. Anderson TJ, Grégoire J, Hegele RA, et al. 2012 Update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29(2):151-167.
11. Perk J, De Backer G, Gohlke H, et al; European Association for Cardiovascular Prevention & Rehabilitation; ESC Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635-1701.
12. Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308(8):788-795.
13. Kavousi M, Elias-Smale S, Rutten JH, et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med. 2012;156(6):438-444.
14. Agatston AS, Janowitz WR, Kaplan G, Gasso J, Hildner F, Viamonte M Jr. Ultrafast computed tomography-detected coronary calcium reflects the angiographic extent of coronary arterial atherosclerosis. Am J Cardiol. 1994;74(12):1272-1274.
15. Ambrosius WT, Polonsky TS, Greenland P, et al. Design of the value of imaging in enhancing the wellness of your heart (VIEW) trial and the impact of uncertainty on power. Clin Trials. 2012;9(2):232-246.
16. Criqui MH, Denenberg JO, Ix JH, et al. Calcium density of coronary artery plaque and risk of incident cardiovascular events. JAMA. doi:10.1001/jama.2013. 282535.
17. Hingorani AD, Psaty BM. Primary prevention of cardiovascular disease: time to get more or less personal? JAMA. 2009;302(19):2144-2145.